In vitro activity of LY281389 and comparison with erythromycin and oral beta-lactams.

LY281389 is a new 14-member ring macrolide which is presently being developed for possible clinical use against bacterial infections. We compared the in vitro activity of LY281389 with erythromycin, ampicillin, augmentin and cephalexin against 610 clinical isolates. The new drug inhibited 97 and 11% of methicillin-sensitive and methicillin-resistant Staphylococcus aureus isolates, respectively, 59% of coagulase-negative staphylococci, 63% of enterococci and 74% of Haemophilus influenzae. All the 171 isolates of Streptococcus Lancefield group A, group B and Streptococcus pneumoniae were susceptible to LY281389 at MIC values ranging between 0.03 and 0.24 micrograms/ml. In vitro activity of LY281389 against the bacteria tested was comparable to that of erythromycin.
AuthorsS M Qadri, Y Ueno, H H Frayha
JournalChemotherapy (Chemotherapy) Vol. 37 Issue 4 Pg. 270-4 ( 1991) ISSN: 0009-3157 [Print] SWITZERLAND
PMID1790725 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Anti-Bacterial Agents
  • beta-Lactams
  • 9-N-(1-propyl)erythromyclamine
  • Erythromycin
  • Anti-Bacterial Agents (pharmacology)
  • Bacteria (drug effects)
  • Drug Resistance, Microbial
  • Erythromycin (analogs & derivatives, pharmacology)
  • Humans
  • beta-Lactams

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: